Table of Contents Author Guidelines Submit a Manuscript
Journal of Biomedicine and Biotechnology
Volume 2012 (2012), Article ID 848042, 10 pages
http://dx.doi.org/10.1155/2012/848042
Research Article

Identification of HLA-A24-Restricted Novel T Cell Epitope Peptides Derived from P-Cadherin and Kinesin Family Member 20A

1Second Department of Surgery, Wakayama Medical University, 811-1 Kimiidera, Wakayama 641-8510, Japan
2OncoTherapy Science Inc. Research Department, Kanagawa 213-0012, Japan
3Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan
4Department of Immunology, Juntendo University School of Medicine, Tokyo 113-8421, Japan

Received 6 February 2012; Revised 9 April 2012; Accepted 9 April 2012

Academic Editor: Soldano Ferrone

Copyright © 2012 Ryuji Osawa et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. Boon, “Tumor antigens recognized by cytolytic T lymphocytes: present perspectives for specific immunotherapy,” International Journal of Cancer, vol. 54, no. 2, pp. 177–180, 1993. View at Publisher · View at Google Scholar · View at Scopus
  2. T. Boon and P. Van der Bruggen, “Human tumor antigens recognized by T lymphocytes,” Journal of Experimental Medicine, vol. 183, no. 3, pp. 725–729, 1996. View at Publisher · View at Google Scholar · View at Scopus
  3. P. van der Bruggen, C. Traversari, P. Chomez et al., “A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma,” Science, vol. 254, no. 5038, pp. 1643–1647, 1991. View at Google Scholar · View at Scopus
  4. V. Brichard, A. Van Pel, T. Wolfel et al., “The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas,” Journal of Experimental Medicine, vol. 178, no. 2, pp. 489–495, 1993. View at Google Scholar · View at Scopus
  5. Y. Kawakami, S. Eliyahu, K. Sakaguchi et al., “Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes,” Journal of Experimental Medicine, vol. 180, no. 1, pp. 347–352, 1994. View at Publisher · View at Google Scholar · View at Scopus
  6. Y. T. Chen, M. J. Scanlan, U. Sahin et al., “A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 5, pp. 1914–1918, 1997. View at Publisher · View at Google Scholar · View at Scopus
  7. S. R. Reynolds, A. Zeleniuch-Jacquotte, R. L. Shapiro et al., “Vaccine-induced CD8+ T-cell responses to MAGE-3 correlate with clinical outcome in patients with melanoma,” Clinical Cancer Research, vol. 9, no. 2, pp. 657–662, 2003. View at Google Scholar · View at Scopus
  8. S. A. Rosenberg, J. C. Yang, D. J. Schwartzentruber et al., “Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma,” Clinical Cancer Research, vol. 9, no. 8, pp. 2973–2980, 2003. View at Google Scholar · View at Scopus
  9. G. Pecher, A. Häring, L. Kaiser, and E. Thiel, “Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a phase I/II clinical trial,” Cancer Immunology, Immunotherapy, vol. 51, no. 11-12, pp. 669–673, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Miyazawa, R. Ohsawa, T. Tsunoda et al., “Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer,” Cancer Science, vol. 101, no. 2, pp. 433–439, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. K. Kono, Y. Mizukami, Y. Daigo et al., “Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer,” Cancer Science, vol. 100, no. 8, pp. 1502–1509, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. K. Okuno, F. Sugiura, J. I. Hida et al., “Phase I clinical trial of a novel peptide vaccine in combination with UFT/LV for metastatic colorectal cancer,” Experimental and Therapeutic Medicine, vol. 2, no. 1, pp. 73–79, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Palmer, J. Parker, S. Modi et al., “Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancer,” Clinical Lung Cancer, vol. 3, no. 1, pp. 49–57, 2001. View at Google Scholar · View at Scopus
  14. T. Nakamura, Y. Furukawa, H. Nakagawa et al., “Genome-wide cDNA microarray analysis of gene expression profiles in pancreatic cancers using populations of tumor cells and normal ductal epithelial cells selected for purity by laser microdissection,” Oncogene, vol. 23, no. 13, pp. 2385–2400, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. K. Taniuchi, H. Nakagawa, M. Hosokawa et al., “Overexpressed P-cadherin/CDH3 promotes motility of pancreatic cancer cells by interacting with p120ctn and activating Rho-family GTPases,” Cancer Research, vol. 65, no. 8, pp. 3092–3099, 2005. View at Google Scholar · View at Scopus
  16. K. Taniuchi, H. Nakagawa, T. Nakamura et al., “Down-regulation of RAB6KIFL/KIF20A, a kinesin involved with membrane trafficking of discs large homologue 5, can attenuate growth of pancreatic cancer cell,” Cancer Research, vol. 65, no. 1, pp. 105–112, 2005. View at Google Scholar · View at Scopus
  17. M. Takeichi, “The cadherins: cell-cell adhesion molecules controlling animal morphogenesis,” Development, vol. 102, no. 4, pp. 639–655, 1988. View at Google Scholar · View at Scopus
  18. F. Lai, A. A. Fernald, N. Zhao, and M. M. Le Beau, “cDNA cloning, expression pattern, genomic structure and chromosomal location of RAB6KIFL, a human kinesin-like gene,” Gene, vol. 248, no. 1-2, pp. 117–125, 2000. View at Publisher · View at Google Scholar · View at Scopus
  19. Y. Ikeda-Moore, H. Tomiyama, K. Miwa et al., “Identification and characterization of multiple HLA-A24-restricted HIV-1 CTL epitopes: strong epitopes are derived from V regions of HIV-1,” Journal of Immunology, vol. 159, no. 12, pp. 6242–6252, 1997. View at Google Scholar · View at Scopus
  20. E. Celis, V. Tsai, C. Crimi et al., “Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 6, pp. 2105–2109, 1994. View at Google Scholar · View at Scopus
  21. H. Ishizaki, T. Tsunoda, S. Wada, M. Yamauchi, M. Shibuya, and H. Tahara, “Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1,” Clinical Cancer Research, vol. 12, no. 19, pp. 5841–5849, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. N. Uchida, T. Tsunoda, S. Wada, Y. Furukawa, Y. Nakamura, and H. Tahara, “Ring finger protein 43 as a new target for cancer immunotherapy,” Clinical Cancer Research, vol. 10, no. 24, pp. 8577–8586, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Wada, T. Tsunoda, T. Baba et al., “Rationale for antiangiogenic cancer therapy with vaccination using epitope peptides derived from human vascular endothelial growth factor receptor 2,” Cancer Research, vol. 65, no. 11, pp. 4939–4946, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. T. Suda, T. Tsunoda, Y. Daigo, Y. Nakamura, and H. Tahara, “Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy,” Cancer Science, vol. 98, no. 11, pp. 1803–1808, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. K. Takeda, N. Yamaguchi, H. Akiba et al., “Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy,” Journal of Experimental Medicine, vol. 199, no. 4, pp. 437–448, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Sultana, C. Tudur Smith, D. Cunningham et al., “Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy,” British Journal of Cancer, vol. 96, no. 8, pp. 1183–1190, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, and M. J. Thun, “Cancer statistics, 2009,” CA Cancer Journal for Clinicians, vol. 59, no. 4, pp. 225–249, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. K. Imai, S. Hirata, A. Irie et al., “Identification of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers,” Clinical Cancer Research, vol. 14, no. 20, pp. 6487–6495, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. K. Imai, S. Hirata, A. Irie et al., “Identification of HLA-A2-restricted CTL epitopes of a novel tumour-associated antigen, KIF20A, overexpressed in pancreatic cancer,” British Journal of Cancer, vol. 104, no. 2, pp. 300–307, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. J. H. Sampson, A. B. Heimberger, G. E. Archer et al., “Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma,” Journal of Clinical Oncology, vol. 28, no. 31, pp. 4722–4729, 2010. View at Publisher · View at Google Scholar · View at Scopus